AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10357421 — intervention group
Group type: COMPARATOR
Intervention: Galectin-3 expression in benign thyroid adenomas, goiters, and normal thyroid tissues
Number of subjects: 172
Study 10357421 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analysis of galectin-3 in isolated epithelial cells from thyroid nodules
Number of subjects: 172
Study 8602658 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil at target concentrations of 0 ng/ml (Group A)
Number of subjects: 20
Study 8602658 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil at target concentrations of 50 ng/ml (Group B)
Number of subjects: 20
Study 8602658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 200 ng/ml (Group C)
Number of subjects: 20
Study 8602658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 400 ng/ml (Group D)
Number of subjects: 20
Study 8602658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0 to 500 ng/ml)
Number of subjects: 20
Study 1777174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg every 6 h)
Number of subjects: 199
Study 1777174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zidovudine and acyclovir (800 mg every 6 h)
Number of subjects: 199
Study 1777174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 7324943 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxy‐vitamin D3, 0.05 or 0.10 micrograms/kg i.v. on the first 3 days of life
Number of subjects: 81
Study 7324943 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 81
Study 31454197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ventilation (Group 1, n=37)
Number of subjects: 74
Study 31454197 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilated group (Group 2, n=37)
Number of subjects: 74
Study 27792047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine (20 ml ropivacaine 0.5% plus 1 ml dexmedetomidine 100 µg/ml)
Number of subjects: 21
Study 27792047 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine plus placebo (20 ml ropivacaine 0.5% plus 1 ml saline)
Number of subjects: 21
Study 27792047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine
Number of subjects: 21
Study 26489511 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection
Number of subjects: 870
Study 26489511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 23413781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg once a day for 3 days) plus hydration (1 mL/kg/h sodium chloride infusion for 24 hours)
Number of subjects: 90
Study 23413781 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (1 mL/kg/h sodium chloride infusion for 24 hours)
Number of subjects: 90
Study 23413781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan plus hydration
Number of subjects: 90
Study 23413781 — intervention group
Group type: COMPARATOR
Intervention: Hydration only
Number of subjects: 90
Study 23413781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan plus hydration (in diabetic subgroup)
Number of subjects: 90
Study 23413781 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (in diabetic subgroup)
Number of subjects: 90
Study 21454091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with regular consultations with the dietitian and multidisciplinary team
Number of subjects: 100
Study 21454091 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 21454091 — intervention group
Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 100
Study 21454091 — intervention group
Group type: COMPARATOR
Intervention: Simple exercise advice
Number of subjects: 100
Study 20046652 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused, structured 9-month SMBG intervention (n=59)
Number of subjects: 159
Study 20046652 — intervention group
Group type: COMPARATOR
Intervention: Regular care based on guidelines (n=64)
Number of subjects: 159
Study 17674975 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT+SRS
Number of subjects: 132
Study 17674975 — intervention group
Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 132
Study 14693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 3305
Study 14693982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3305
Study 12066082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate
Number of subjects: 0
Study 12066082 — intervention group
Group type: COMPARATOR
Intervention: Other tocolytic
Number of subjects: 0
Study 12066082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9620911 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human IL-4
Number of subjects: 8
Study 9620911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle inhalation)
Number of subjects: 8
Study 7907426 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 or 24 micrograms)
Number of subjects: 16
Study 7907426 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 16
Study 7907426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2668247 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 4.5 mg/kg once daily (od)
Number of subjects: 114
Study 2668247 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 1.5 mg/kg thrice daily (tid)
Number of subjects: 114
Study 2668247 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (od and tid)
Number of subjects: 114
Study 324566 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 31
Study 324566 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 31
Study 31425966 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT)
Number of subjects: 476
Study 31425966 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 476
Study 29415833 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (6 g/day for 7 days)
Number of subjects: 8
Study 29415833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24839047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl orally disintegrating tablet
Number of subjects: 42
Study 24839047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23816726 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment for Helicobacter pylori infection
Number of subjects: 50
Study 21820166 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders sent to health workers' mobile phones on malaria case-management for 6 months
Number of subjects: 119
Study 21820166 — intervention group
Group type: COMPARATOR
Intervention: No text-message reminders (Control group)
Number of subjects: 119
Study 19399308 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified Respiratory Educators (CREs)
Number of subjects: 198
Study 19399308 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 198
Study 16675511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (50 mm Hg)
Number of subjects: 10
Study 16675511 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (35 mm Hg)
Number of subjects: 10
Study 14744521 — intervention group
Group type: EXPERIMENTAL
Intervention: Shown‐Discrepancy Group
Number of subjects: 0
Study 14744521 — intervention group
Group type: COMPARATOR
Intervention: No‐Demonstration Group
Number of subjects: 0
Study 11333069 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity; lorazepam PRN (3 mg/day) was allowed.
Number of subjects: 228
Study 11333069 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with unilateral or bilateral application.
Number of subjects: 228
Study 11333069 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) for bipolar patients (BP I and BP II).
Number of subjects: 228
Study 8979175 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics exercise regimen
Number of subjects: 60
Study 8979175 — intervention group
Group type: COMPARATOR
Intervention: Established protocol
Number of subjects: 60
Study 8979175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 8507109 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 13
Study 8507109 — intervention group
Group type: COMPARATOR
Intervention: Regular oral diet (Control)
Number of subjects: 13
Study 8507109 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN (1 patient with jejunum obtained)
Number of subjects: 13
Study 2435356 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 10 mg/day for 5 weeks
Number of subjects: 45
Study 2435356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29452603 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (6% in 40% O2 and 60% air)
Number of subjects: 42
Study 29452603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% in 40% O2 and 60% air)
Number of subjects: 42
Study 29452603 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nesfatin levels between groups
Number of subjects: 42
Study 27274216 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 33
Study 27274216 — intervention group
Group type: EXPERIMENTAL
Intervention: Edi catheter insertion
Number of subjects: 33
Study 24698126 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy (hot pack warmed to 50 °C)
Number of subjects: 66
Study 24698126 — intervention group
Group type: COMPARATOR
Intervention: Placebo heat therapy (hot pack warmed to 37 °C)
Number of subjects: 66
Study 24698126 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy
Number of subjects: 66
Study 23639030 — intervention group
Group type: EXPERIMENTAL
Intervention: Life storybook creation process (intervention group, n = 14)
Number of subjects: 26
Study 23639030 — intervention group
Group type: COMPARATOR
Intervention: Non-life storybook (control group, n = 12)
Number of subjects: 26
Study 21234866 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus prulifloxacin (600 mg single oral dose 6 hours after instillation)
Number of subjects: 43
Study 21234866 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 43
Study 17535522 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sex physics classes
Number of subjects: 401
Study 17535522 — intervention group
Group type: COMPARATOR
Intervention: Coeducational physics classes
Number of subjects: 401
Study 17535522 — intervention group
Group type: COMPARATOR
Intervention: Mixed-sex classes
Number of subjects: 401
Study 16402604 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal analysis of coherence and transfer function between systolic pressure (SP) and RR interval variability in patients with neurally mediated syncope.
Number of subjects: 16
Study 16402604 — intervention group
Group type: COMPARATOR
Intervention: Causal analysis of coherence and transfer function between systolic pressure (SP) and RR interval variability in control subjects.
Number of subjects: 16
Study 12819631 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal ointment applied to affected joint(s) for 42 days
Number of subjects: 36
Study 12819631 — intervention group
Group type: COMPARATOR
Intervention: Sham ointment applied to affected joint(s) for 42 days
Number of subjects: 36
Study 12819631 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal ointment
Number of subjects: 36
Study 12411810 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia initiated prior to incision
Number of subjects: 157
Study 12411810 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia initiated at the time of rib approximation
Number of subjects: 157
Study 12411810 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 157
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT; 3 days/wk resistance training)
Number of subjects: 30
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT; 3 days/wk jogging and/or running + resistance training)
Number of subjects: 30
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET; 3 days/wk jogging and/or running)
Number of subjects: 30
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 30
Study 9688748 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 30
Study 8061263 — intervention group
Group type: EXPERIMENTAL
Intervention: pipecuronium (0.15 mg/kg)
Number of subjects: 30
Study 8061263 — intervention group
Group type: COMPARATOR
Intervention: doxacurium (0.08 mg/kg)
Number of subjects: 30
Study 8061263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (pipecuronium and doxacurium)
Number of subjects: 30
Study 2456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation plus preoperative and postoperative therapy with cisplatin, vindesine, and bleomycin (n = 19)
Number of subjects: 39
Study 2456424 — intervention group
Group type: COMPARATOR
Intervention: Operation only (n = 20)
Number of subjects: 39
Study 2456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients responding to chemotherapy preoperatively
Number of subjects: 39
Study 2456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to chemotherapy
Number of subjects: 39
Study 2456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving only operation
Number of subjects: 39
Study 2456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of less than 10%
Number of subjects: 39
Study 30829209 — intervention group
Group type: EXPERIMENTAL
Intervention: Candicure (polyherbal formulation)
Number of subjects: 150
Study 30829209 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole therapy (control drug)
Number of subjects: 150
Study 28340904 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE (group-based motivational interviewing intervention)
Number of subjects: 200
Study 28340904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 25966264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba tablets (GBT) 19.2 mg three times a day for 3 months along with conventional anti-platelet aggregation treatment
Number of subjects: 80
Study 25966264 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with 75 mg aspirin three times a day for 3 months
Number of subjects: 80
Study 25966264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba tablets (GBT)
Number of subjects: 80
Study 23859768 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia program (viewing at least 4 options to discipline a child)
Number of subjects: 258
Study 23859768 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care with resident physician (control group)
Number of subjects: 258
Study 22398345 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga program (twice-weekly classes for 8 weeks)
Number of subjects: 38
Study 22398345 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual daily routines)
Number of subjects: 38
Study 19212259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 441
Study 17127232 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11), leucovorin (LV), and 5-fluorouracil (5FU)
Number of subjects: 160
Study 17127232 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin (LV) and 5-fluorouracil (5FU)
Number of subjects: 160
Study 14713747 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride
Number of subjects: 18882
Study 14713747 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18882
Study 11370751 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal plate therapy
Number of subjects: 20
Study 11370751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no palatal plate therapy)
Number of subjects: 20
Study 9212478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 40
Study 9212478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine (MST)
Number of subjects: 40
Study 9212478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 7962684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 43
Study 7962684 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 43
Study 3663878 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of adinazolam (40 mg)
Number of subjects: 8
Study 3663878 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state dosing of adinazolam (final dose rates of 1, 2, and 3 mg h‐1)
Number of subjects: 8
Study 30737889 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected meridian acupuncture
Number of subjects: 428
Study 30737889 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-affected meridian acupuncture
Number of subjects: 428
Study 30737889 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 428
Study 30737889 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 428
Study 30737889 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (pooled groups)
Number of subjects: 428
Study 29364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Lamivudine (LAM) and Adefovir Dipivoxil (ADV)
Number of subjects: 127
Study 29364091 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week optimized therapy of Adefovir Dipivoxil (ADV) after Lamivudine (LAM)
Number of subjects: 127
Study 29364091 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week optimized therapy of Adefovir Dipivoxil (ADV) after Lamivudine (LAM)
Number of subjects: 127
Study 29364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 127
Study 29364091 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy, 12-week optimized therapy, and ETV monotherapy
Number of subjects: 127
Study 25530151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF) 1.4-10.9 mg/kg bw
Number of subjects: 15
Study 25530151 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate 0.1-10 mg/kg bw
Number of subjects: 15
Study 25530151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate (3 or 8.5 mg/kg bw) followed by CF (2.7 or 10.9 mg/kg bw)
Number of subjects: 15
Study 25530151 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study 25530151 — intervention group
Group type: COMPARATOR
Intervention: CF-free drink (micro- and macronutrient-matched)
Number of subjects: 15
Study 24119879 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reduction (Group A, n=36)
Number of subjects: 73
Study 24119879 — intervention group
Group type: COMPARATOR
Intervention: Fusion in situ (Group B, n=37)
Number of subjects: 73
Study 24119879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 73
Study 21610559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume wound infiltration with ropivacaine 0.2% with epinephrine (10 μg/mL)
Number of subjects: 120
Study 21610559 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 120
Study 19479528 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring approximately Web (Web-based intervention)
Number of subjects: 103
Study 19479528 — intervention group
Group type: COMPARATOR
Intervention: Non-Web user group (Control)
Number of subjects: 103
Study 16972834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg.kg‐1 tramadol in 0.2 ml.kg‐1 saline)
Number of subjects: 75
Study 16972834 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.2 ml.kg‐1 0.25% bupivacaine)
Number of subjects: 75
Study 16972834 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tramadol (2 mg.kg‐1 tramadol injected 20 minutes before end of surgery)
Number of subjects: 75
Study 15163651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid
Number of subjects: 0
Study 15163651 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 0
Study 10908213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (50, 150, and 300 mg administered at 2-hour intervals)
Number of subjects: 7
Study 9156659 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (molgramostim) 8 mg/kg/d for 14 days
Number of subjects: 40
Study 9156659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9156659 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (molgramostim)
Number of subjects: 40
Study 7798818 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine slow release tablet (MST)
Number of subjects: 49
Study 7798818 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate solution (MSS)
Number of subjects: 49
Study 3521561 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution
Number of subjects: 40
Study 3521561 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of timolol (control)
Number of subjects: 40
Study 29883597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS (1200 pulses at 20 Hz followed by 1200 pulses per session)
Number of subjects: 65
Study 29883597 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral right rTMS (2400 pulses at 20 Hz)
Number of subjects: 65
Study 29883597 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 65
Study 29883597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS
Number of subjects: 65